Mandate

Vinge advises Lantmännen in connection with its acquisition of the remaining shares in Scandbio

Vinge has advised Lantmännen in connection with its acquisition of the remaining shares in Scandbio AB. Scandbio AB was founded in 2014 when Lantmännen merged its operations with the Finnish company Neova. Both owners have held an equal number of shares in the 50/50 joint venture company since 2014.

Scandbio is Sweden’s largest company in the fixed refined forestry fuel sector with an annual turnover of around MSEK 1 000. The company is headquartered in Jönköping with operations at five sites in Sweden and one in Latvia. Scandbio manufactures, markets and sells wood pellets fuel to Sweden, Denmark and the Baltic States as well as stable pellets for the Swedish market. The company provides both industrial facilities as well as municipal and state-owned operations, local entrepreneurs and individual home owners with 100 per cent renewable energy.

The transaction is subject to the requisite approvals by the competition authorities.

Vinge’s team consisted of Christina Kokko and Elsie Nassar (M&A) together with Marcus Glader, Johan Wahlbom and Jesper Ekman (Merger filing).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024